News und Analysen
![LivaNova Announces New Senior Secured Credit Facility](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
LivaNova Announces New Senior Secured Credit Facility
LivaNova PLC (NASDAQ:LIVN) (“The Company” or “LivaNova”) today announced its entry into a five-year $450 million senior secured credit facility (the “Credit Facility”) through its wholly owned U.S
![LivaNova Announces Proposed Private Offering of $250 Million of Cash Exchangeable Senior Notes](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
LivaNova Announces Proposed Private Offering of $250 Million of Cash Exchangeable Senior Notes
LivaNova PLC (NASDAQ:LIVN) ("LivaNova") today announced its intention to offer $250 million aggregate principal amount of cash exchangeable senior notes due 2025 through its wholly owned U.S
![Clovis Oncology Announces Completion of Target Enrollment in the ATHENA Trial, a Phase 3 Maintenance Treatment Study in Front-line, Newly-Diagnosed Advanced Ovarian Cancer](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Clovis Oncology Announces Completion of Target Enrollment in the ATHENA Trial, a Phase 3 Maintenance Treatment Study in Front-line, Newly-Diagnosed Advanced Ovarian Cancer
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today the completion of target patient enrollment in the Clovis-sponsored Phase 3 ATHENA trial evaluating the combination of Clovis’ Rubraca®
![Acadia Healthcare Announces Pricing of $450 Million Senior Notes Due 2028 and Intention to Redeem Its 2021 Notes and 2022 Notes](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Acadia Healthcare Announces Pricing of $450 Million Senior Notes Due 2028 and Intention to Redeem Its 2021 Notes and 2022 Notes
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) (the “Company” or “Acadia”) announced today the pricing of its previously announced private offering (the “Offering”) of $450 million in aggregate
![Acadia Healthcare Announces Launch of $450 Million Senior Notes Offering](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
Acadia Healthcare Announces Launch of $450 Million Senior Notes Offering
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) (the “Company” or “Acadia”) announced today that it has launched a private offering (the “Offering”) of senior notes due 2028 (the “Notes”), subject
![Pfizer Announces Positive Top-Line Results from JADE TEEN Trial of Abrocitinib in Adolescents with Moderate-to-Severe Atopic Dermatitis](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Pfizer Announces Positive Top-Line Results from JADE TEEN Trial of Abrocitinib in Adolescents with Moderate-to-Severe Atopic Dermatitis
Pfizer Inc. (NYSE: PFE) announced today positive top-line results from the Phase 3 JADE TEEN study of abrocitinib, an investigational oral once-daily Janus kinase 1 (JAK1) inhibitor, in patients 12
![Curadigm Announces Publication of Results Using Proprietary Nanoprimer to Improve RNA Therapeutics in Collaboration With the Langer Lab](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Curadigm Announces Publication of Results Using Proprietary Nanoprimer to Improve RNA Therapeutics in Collaboration With the Langer Lab
Curadigm today announced the publication, with Prof. Robert Langer’s lab at MIT, of pre-clinical in vivo results showing that its Nanoprimer can improve the efficacy of RNA-based therapeutics. This
![NANOBIOTIX Spinoff Curadigm Validates Novel Nanoprimer Technology in RNA Therapeutics](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
NANOBIOTIX Spinoff Curadigm Validates Novel Nanoprimer Technology in RNA Therapeutics
Regulatory News:
NANOBIOTIX (Paris:NANO) (Euronext: NANO - ISIN: FR0011341205 – the “Company”), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today
![Illumina Receives First FDA Emergency Use Authorization for a Sequencing-Based COVID-19 Diagnostic Test](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Illumina Receives First FDA Emergency Use Authorization for a Sequencing-Based COVID-19 Diagnostic Test
Illumina, Inc. (NASDAQ: ILMN) is paving the way for large-scale, next-generation sequencing-based (NGS) COVID-19 testing. Today, the U.S. Food and Drug Administration (FDA) issued an Emergency Use
![Quidel Receives Amended Emergency Authorization for Rapid Antigen COVID-19 Diagnostic Assay Using Sofia 1 Instrument](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Quidel Receives Amended Emergency Authorization for Rapid Antigen COVID-19 Diagnostic Assay Using Sofia 1 Instrument
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has
![Antibe Therapeutics Announces $25 Million Bought Deal Unit Offering](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Antibe Therapeutics Announces $25 Million Bought Deal Unit Offering
Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV:ATE) today announced that it has entered into a bought deal agreement with a syndicate of underwriters led by Bloom Burton Securities Inc
![New Capability in Vault PromoMats to Speed Packaging Promotional Materials for FDA Submission](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
New Capability in Vault PromoMats to Speed Packaging Promotional Materials for FDA Submission
Veeva Systems (NYSE: VEEV) today announced at Veeva Summit Online a new capability in Veeva Vault PromoMats to speed the digital submission of promotional materials for accelerated approval
![Veeva Announces New Solution to Accelerate Insights for Key Account Management](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Veeva Announces New Solution to Accelerate Insights for Key Account Management
Today at Veeva Summit Online, Veeva Systems (NYSE: VEEV) announced Veeva Link for KAM, a new solution that gives commercial and medical teams accurate customer data and real-time insights for key
![Aurinia Presents Additional AURORA Pivotal Trial Safety Data at the ERA-EDTA Virtual Congress 2020](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Aurinia Presents Additional AURORA Pivotal Trial Safety Data at the ERA-EDTA Virtual Congress 2020
Aurinia Pharmaceuticals Inc. (Nasdaq:AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple indications
![Sensorion Announces Positive Preliminary Preclinical Data From Its Otoferlin Gene Therapy Program](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Sensorion Announces Positive Preliminary Preclinical Data From Its Otoferlin Gene Therapy Program
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
![Evotec: US-Partnerschaft zeigt Potential von neuer Sparte!](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Evotec: US-Partnerschaft zeigt Potential von neuer Sparte!
Evotec (WKN: 566480) gibt heute eine neue US-Partnerschaft bekannt. Mit dem globalen Auftragsentwickler und -hersteller Advanced BioScience Laboratories wird der Einsatz gegen das HI-Virus
![Technology Veteran Brent Bowman to Become Veeva Chief Financial Officer](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Technology Veteran Brent Bowman to Become Veeva Chief Financial Officer
Veeva Systems (NYSE: VEEV) today announced that Brent Bowman will become the company’s next chief financial officer. Bowman will assume the role of CFO after a transition period of approximately 90
![IMV to Present at Raymond James' Human Health Innovation Conference](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
IMV to Present at Raymond James' Human Health Innovation Conference
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of targeted cancer immunotherapies and vaccines against infectious diseases, today announced
![Nanobiotix Secures €10M in Non-Dilutive Financing](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Nanobiotix Secures €10M in Non-Dilutive Financing
Regulatory News:
NANOBIOTIX (Paris:NANO) (Euronext: NANO - ISIN: FR0011341205 – the “Company”), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today
![Aurinia Presents AURORA Pivotal Trial Subgroup Analysis at the EULAR 2020 E-Congress](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Aurinia Presents AURORA Pivotal Trial Subgroup Analysis at the EULAR 2020 E-Congress
Aurinia Pharmaceuticals Inc. (Nasdaq:AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple indications
![Lysogene announces important updates on AAVance phase 2/3 clinical trial with LYS-SAF302 in MPS IIIA](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Lysogene announces important updates on AAVance phase 2/3 clinical trial with LYS-SAF302 in MPS IIIA
Regulatory News:
Lysogene (Paris:LYS) (FR0013233475 – LYS), a Phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, today announced that, following discussions
![Premier Inc. Recommends 24 Regulatory Waivers Be Made Permanent After COVID-19](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Premier Inc. Recommends 24 Regulatory Waivers Be Made Permanent After COVID-19
Premier Inc. (NASDAQ: PINC) today provided the U.S. Department of Health and Human Services (HHS) and Congress with a list of 24 regulatory waivers that should be made permanent as the COVID-19
![Dexcom Announces Upcoming Conference Presentation](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Dexcom Announces Upcoming Conference Presentation
DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on Dexcom at the following upcoming investor conference:
-
Steve Pacelli, Executive Vice President, Strategy and
![Sensorion to attend Citi European Healthcare Conference](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Sensorion to attend Citi European Healthcare Conference
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotech company which specializes in the development of novel therapies to restore, treat and prevent
![Complete Results from Second Pivotal Monotherapy Study of Abrocitinib Published in JAMA Dermatology](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Complete Results from Second Pivotal Monotherapy Study of Abrocitinib Published in JAMA Dermatology
Pfizer Inc. (NYSE: PFE) announced today that JAMA Dermatology has published complete results from the second Phase 3 monotherapy pivotal study (JADE MONO-2) of abrocitinib, an investigational oral